CIR
ALXN

Clear Investment Research’s Alexion Pharmaceuticals ALXN Stock Holding History

Clear Investment Research’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3
Closed – – 439
2019
Q3 		$0 Hold
3
– – ﹤0.01% 428
2019
Q2 		$0 Hold
3
– – ﹤0.01% 429
2019
Q1 		$0 Hold
3
– – ﹤0.01% 421
2018
Q4 		$0 Hold
3
– – ﹤0.01% 420
2018
Q3 		$0 Buy
+3
New +$376 ﹤0.01% 422

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Clear Investment Research's ALXN Position: Q4 2019 in Review

Clear Investment Research sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 3 shares.

Clear Investment Research first reported a position in ALXN in Q3 2018 and held it in 5 quarters. The position peaked at $0 in Q3 2019. 667 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Clear Investment Research reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Clear Investment Research sold 3 Alexion Pharmaceuticals shares in Q4 2019.
  • Clear Investment Research first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 5 quarters.
  • Clear Investment Research's Alexion Pharmaceuticals position peaked at $0 in Q3 2019.
  • 667 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Clear Investment Research's 13F filing for Q4 2019, filed 4 Feb 2020.